NCT03566563 (EPIC) is a clinical trial of Screening in Hepatitis C, sponsored by Changi General Hospital.

Who is sponsoring NCT03566563?

NCT03566563 is sponsored by Changi General Hospital.

What drugs are being tested in NCT03566563?

Interventions in NCT03566563: Screening.

What condition does NCT03566563 study?

NCT03566563 studies Hepatitis C.

Is NCT03566563 still recruiting?

NCT03566563 is currently completed. Last updated 8 October 2020.

Last reviewed 2020-10-08 · How we verify

NCT03566563: EPIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epidemiology of Chronic Hepatitis C and Disease Modelling

Completed Last updated 8 October 2020

What this trial tests

trial testing Screening in Hepatitis C in 520 participants. Completed in 29 May 2020.

Timeline

21 February 2017

Primary endpoint
7 February 2020

29 May 2020

Quick facts

Lead sponsor	Changi General Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	520
Start date	21 February 2017
Primary completion	7 February 2020
Estimated completion	29 May 2020
Sites	1 location across Singapore

Drugs / interventions tested

Screening

Conditions studied

Hepatitis C — all drugs for Hepatitis C →

Sponsor

Changi General Hospital

Who can join

21 and older, any sex, with Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hepatitis C (HCV) is a major health problem amongst people who inject drugs (PWID) and have limited contact with health care services. Halfway houses (HH) serve to reintegrate former drug users into society. Strategies to eliminate HCV must focus on screening for HCV amongst HH. Linkage to care for PWID population is an issue globally. The aim is to determine the sero-prevalence, demographics, disease distribution and factors associated with the risk of HCV transmission amongst former drug users at Halfway Houses. The secondary aim would be to determine the best models of care that can be used to link these individuals to existing healthcare services in a pragmatic, randomised fashion Halfway Houses are invited to participate in a program of HCV education, point-of-care screening using Oraquick test and staging with Fibroscan® by a small mobile team of healthcare workers. A detailed survey regarding illicit drug injecting practices is performed. Those who are tested positive are referred to medical care. It is anticipated that the prevalence of Hepatitis C within the drug injecting population along with the stages of liver disease such that models for disease burden can be determined.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Point-of-care hepatitis C screening with direct access referral to improve linkage to care among halfway house residents: a pilot randomised study.
Hsiang JC, Sinnaswami P, Lee MY, Zhang MM, et al · · 2022 · cited 16× · PMID 32729280 · DOI 10.11622/smedj.2020116

Verify or expand the search:

Other trials of Screening

Trials testing the same drug.

NCT07143669 — Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations · recruiting
NCT07225374 — Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC · Phase 2 · recruiting
NCT07235332 — Assessing Toxic Metal Exposure From Vegetarian/Vegan, Omnivorous, and Low-carb Diets in Israel. · enrolling by invitation
NCT06887569 — Using Financial Incentives and Screening to Increase Engagement With Mental Health Services Among College Students in Ch · NA · completed
NCT06439901 — Optimizing Bronchopulmonary Cancer Screening · NA · recruiting

Other recruiting trials for Hepatitis C

Currently open trials in the same condition.

NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
NCT05208697 — Tele-Harm Reduction · NA · active not recruiting

Other Changi General Hospital trials

Trials by the same sponsor.

NCT07297745 — Trial of Aldosterone-hybrid SteRoid for Guiding curablE Treatment of Primary Aldosteronism (TARGET-PA) · NA · not yet recruiting
NCT07205133 — A Randomized Controlled Trial Comparing Whole Body Vibration Therapy With Usual Care and Usual Care to Improve Muscle He · NA · recruiting
NCT06970717 — Programmable Smart Watch for Remote Pre-habilitation/Rehabilitation Monitoring · NA · not yet recruiting
NCT06890169 — OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities · NA · recruiting
NCT06304415 — Elevated Lipoprotein(a) in Hospital Staff · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03566563 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Changi General Hospital
Last refreshed: 8 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03566563.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing